Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Popular weight-loss and type 2 diabetes drugs such as Wegovy and Ozempic ... including one that works on a similar hormone to GLP-1 that is currently in phase 2 clinical trials.

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

LITTLE ROCK (KATV) — GLP-1 drugs are making waves in the world of weight loss and health management, but what exactly are they? Allison Debussy, an APRN with Baptist Health Weight Loss Center ...

On April 17, 2025, Eli Lilly reported that their experimental, orally-dosed GLP-1 drug (orfoglipron) resulted in lower blood sugar and lower body weight after 40 weeks in a phase 3 clinical trial.

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight ... So, Eli Lilly appears to have solid liquidity for the next twelve months. Long-term debt was $28.644 ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Research published this week has found that GLP-1 drugs are associated with a lower ... have launched two large-scale phase III trials testing semaglutide for people with early Alzheimer’s ...

but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the first of several phase 3 drug trials. The jump in share price propelled the stock ...